Question special
Lead Moderator

I am delighted to be part of the discussion about Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicenter international randomized controlled trial. Thank you to the authors for their important contribution to the literature as we continually seek to improve the perinatal care of women with Type 1 diabetes. I would also like to thank our experts for joining us.
Based on the author's findings, the advantage of CGM was that pregnant users spent more time in target range and less time in hyperglycemia, without an increase in hypoglycemic episodes. What is the role of glycemic variability and glucose excursions in fetal growth and neonatal hyperglycemia?